Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

Neurobiology of Aging

Volumn 33, Issue 2, 2012, Pages 265-276

  Gengler, Simon ^a   McClean, Paula L ^a   McCurtin, Ruth ^a   Gault, Victor A ^a   Hölscher, Christian ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Blood brain barrier; Brain; Diabetes; Insulin signaling; Neurons; Neuropeptide; Synaptic plasticity

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GLUCAGON LIKE PEPTIDE 1; INCRETIN; PRESENILIN 1; UNCLASSIFIED DRUG; VALINE 8 GLUCAGON LIKE PEPTIDE 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; HISTOLOGY; LONG TERM POTENTIATION; MALE; MICROGLIA; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNAPTIC TRANSMISSION; TREATMENT RESPONSE;

ALZHEIMER DISEASE; ANIMALS; GLUCAGON-LIKE PEPTIDE 1; LONG-TERM POTENTIATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONAL PLASTICITY; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PRESENILIN-1; SYNAPSES; TREATMENT OUTCOME;

EID: 82755176046     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.02.014     Document Type: Article

References (63)

1. Abbas T., Faivre E., Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res 2009, 205:265-271.
2. Aubert-Pouessel A., Venier-Julienne M.C., Clavreul A., Sergent M., Jollivet C., Montero-Menei C.N., Garcion E., Bibby D.C., Menei P., Benoit J.P. In vitro study of GDNF release from biodegradable PLGA microspheres. J. Control. Release 2004, 95:463-475.
3. Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmeliet P., Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004, 429:413-417.
4. Biessels G.J., De Leeuw F.E., Lindeboom J., Barkhof F., Scheltens P. Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J. Neurol. Neurosurg. Psychiatry 2006, 77:304-307.
5. Biswas S.C., Buteau J., Greene L.A. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem. Res 2008, 33:1845-1851.
6. Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Muller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., Laferla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13594-13599. [PubMed: 19633196].
7. Bondolfi L., Calhoun M., Ermini F., Kuhn H.G., Wiederhold K.H., Walker L., Staufenbiel M., Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J. Neurosci 2002, 22:515-522.
8. Bradbury J. Hope for AD with NGF gene-therapy trial. Lancet Neurol 2005, 4:335.
9. Burger W., Burge M. Digital Imaging Processing - An Algorhythmic Introduction Using Java 2009, Springer Verlag, Berlin.
10. Carro E., Torres-Aleman I. Insulin-like growth factor I and Alzheimer's disease: therapeutic prospects?. In Expert Rev. Neurother 2004, 4:79-86.
11. Carro E., Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur. J. Pharmacol 2004, 490:127-133.
12. Chen Y., Chad J.E., Wheal H.V. Synaptic release rather than failure in the conditioning pulse results in paired-pulse facilitation during minimal synaptic stimulation in the rat hippocampal CA1 neurones. Neurosci. Lett 1996, 218:204-208.
13. Clarris H.J., Nurcombe V., Small D.H., Beyreuther K., Masters C.L. Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer's disease from hippocampal explants. J. Neurosci. Res 1994, 38:248-258.
14. Covaceuszach S., Capsoni S., Ugolini G., Spirito F., Vignone D., Cattaneo A. Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr. Alzheimer Res 2009, 6:158-170.
15. Cummings B.J., Mason A.J., Kim R.C., Sheu P.C., Anderson A.J. Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging. Neurobiol. Aging 2002, 23:161-170.
16. Dickson D.W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol 1997, 56:321-339.
17. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med 2003, 9. 1173-117.
18. Gault V., Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur. J. Pharmacol 2008, 587:112-117.
19. Gault V.A., Flatt P.R., O'Harte F.P. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem. Biophys. Res. Commun 2003, 308:207-213.
20. Gault V.A., Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur. J. Pharmacol 2008, 587:112-117.
21. Gengler S., Gault V., Harriott P., Hölscher C. Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background. Exp. Brain Res 2007, 179:621-630.
22. Gengler S., Hamilton A., Hölscher C. Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice. PLoS ONE 2010, 10.1371/journal.pone.0009764.
23. Gilman C.P., Perry T., Furukawa K., Grieg N.H., Egan J.M., Mattson M.P. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J. Neurochem 2003, 87:1137-1144.
24. Green B.D., Flatt P.R. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract. Res. Clin. Endocrinol. Metab 2007, 21:497-516.
25. Green B.D., Gault V.A., Flatt P.R., Harriott P., Greer B., O'Harte F.P. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch. Biochem. Biophys 2004, 428:136-143.
26. Green B.D., Gault V.A., O'Harte F.P., Flatt P.R. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Diabetes Obes. Metab 2005, 7:595-604.
27. Green B.D., Lavery K.S., Irwin N., O'Harte F.P., Harriott P., Greer B., Bailey C.J., Flatt P.R. Novel GLP-1 analogue (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta cell function after 3 weeks daily administration in obese diabetic (ob/ob) mice. J. Pharmacol. Exp. Ther 2006, 318:914-921.
28. Gregory-Evans K., Chang F., Hodges M.D., Gregory-Evans C.Y. Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Mol. Vis 2009, 15:962-973.
29. Hamilton A., Holscher C. Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. Neuroreport 2009, 20:1161-1166.
30. Heese K., Low J.W., Inoue N. Nerve growth factor, neural stem cells and Alzheimer's disease. Neuro Signals 2006, 15:1-12.
31. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol 2004, 490:115-125. [PubMed: 15094085,15094084,15094082,15094078,15094071,15094068].
32. Hwang D.H., Lee H.J., Park I.H., Seok J.I., Kim B.G., Joo I.S., Kim S.U. Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther 2009, 16:1234-1244.
33. Hölscher C., Gengler S., Gault V., Harriott P., Mallot H. Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur. J. Pharmacol 2007, 561:85-90.
34. Hölscher C., Li L. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's Disease?. Neurobiol. Aging 2008, 10.1016/j.neurobiolaging.2008.08.023.
35. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord 2003, 27:313-318.
36. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci 2002, 18:7-14.
37. Kordower J.H., Mufson E.J., Fox N., Martel L., Emerich D.F. Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates. Exp. Neurol 1997, 145:586-591.
38. Lee H.J., Kim K.S., Park I.H., Kim S.U. Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS ONE 2007, 2:e156.
39. Leech C., Habener J. Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin. J. Biol. Chem 1997, 272:17987-17993.
40. Li L., Hölscher C. Common pathological processes in Alzheimer Disease and Type 2 Diabetes: a review. Brain Res. Rev 2007, 56:384-402.
41. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63:1187-1192.
42. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., Rockenstein E., Chao M.V., Koo E.H., Geschwind D., Masliah E., Chiba A.A., Tuszynski M.H. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med 2009, 15:331-337.
43. Nagano I., Shiote M., Murakami T., Kamada H., Hamakawa Y., Matsubara E., Yokoyama M., Moritaz K., Shoji M., Abe K. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Rev 2005, 27:768-772.
44. Okamoto N., Hore S., Akazawa C., Hayashi Y., Shigemoto R., Mizuno N., Nakanishi S. Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J. Biol. Chem 1994, 269:1231-1236.
45. Paresce D., Chung H., Maxfield F. Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J. Biol. Chem 1997, 14:29390-29397.
46. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res 2003, 72:603-612.
47. Perry T.A., Greig N.H. A new Alzheimer's disease interventive strategy: GLP-1. Curr. Drug Targets 2004, 5:565-571.
48. Poon W.W., Blurton-Jones M., Tu C.H., Feinberg L.M., Chabrier M.A., Harris J.W., Jeon N.L., Cotman C.W. beta-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol. Aging 2009, 10.1016/j.neurobiolaging.2009.05.012.
49. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006, 7:940-946.
50. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med 2004, 82:510-529.
51. Sarkar S., Fekete C., Legradi G., Lechan R.M. Glucagon like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 2003, 985:163-168.
52. Schulte-Herbruggen O., Braun A., Rochlitzer S., Jockers-Scherubl M.C., Hellweg R. Neurotrophic factors - a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases?. Curr. Med. Chem 2007, 14:2318-2329.
53. Schulz P.E., Cook E.P., Johnston D. Using paired-pulse facilitation to probe the mechanisms for long-term potentiation. J. Physiol. Paris 1995, 89:3-9.
54. Shi L., Linville M.C., Tucker E.W., Sonntag W.E., Brunso-Bechtold J.K. Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus. Cereb. Cortex 2005, 15:571-577.
55. Sorenson E.J., Windbank A.J., Mandrekar J.N., Bamlet W.R., Appel S.H., Armon C., Barkhaus P.E., Bosch P., Boylan K., David W.S., Feldman E., Glass J., Gutmann L., Katz J., King W., Luciano C.A., McCluskey L.F., Nash S., Newman D.S., Pascuzzi R.M., Pioro E., Sams L.J., Scelsa S., Simpson E.P., Subramony S.H., Tiryaki E., Thornton C.A. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008, 71:1770-1775.
56. Steen E., Terry B.M., Rivera E., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes?. J. Alzheimers Dis 2005, 7:63-80.
57. Suzuki M., Fujikura K., Inagaki N., Seino S., Takata K. Localization of the ATP-sensitive K+ channel subunit Kir62 in mouse pancreas. Diabetes 1997, 46:1440-1444.
58. Terzi D., Zachariou V. Adeno-associated virus-mediated gene delivery approaches for the treatment of CNS disorders. Biotechnol. J 2008, 3:1555-1563.
59. Tsai M.L., Shen B., Leung L.S. Seizures induced by GABAB-receptor blockade in early-life induced long-term GABA(B) receptor hypofunction and kindling facilitation. Epilepsy Res 2008, 79:187-200.
60. Wheeler D.B., Randall A., Tsien R.W. Roles of N-type and Q-type Ca2+ channels in supporting hippocampal synaptic transmission. Science 1994, 264:107-111.
61. Wilcock D.M., Gordon M.N., Morgan D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat. Protoc 2006, 1:1591-1595.
62. Winder D.G., Conn P.J. Activation of metabotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine. J. Neurosci 1993, 13:38-44.
63. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Natl. Rev. Neurol 2009, 5:311-322.